The National Health Service in England could double the annual payments it offers companies under its pioneering subscription-style contracts for incentivizing them to develop new antibiotics from £10m ($12.90m) to £20m, where outstanding clinically based criteria are met.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?